I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Angelman Syndrome

Angelman Syndrome

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Jul 26 / Roche and Genentech
A Phase IIa Multicenter Study to Investigate the Pharmacokinetics, Safety and Pharmacodynamic Effects of Alogabat in Children and Adolescents With Angelman Syndrome Deletion Genotype
The ALDEBARAN trial will confirm age-adjusted pediatric dose levels for alogabat, a small molecule, selective, positive allosteric modulator of GABAA α5 receptor, in individuals aged 5 to 17 years with Angelman syndrome deletion genotype. The trial will also establish the proof of mechanism for alogabat by evaluating its effects on EEG beta-band power, a biomarker of GABAA receptor function, which is altered in individuals with Angelman syndrome deletion genotype.
Neuroscience Angelman Syndrome ASF-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jul 26 / Roche and Genentech
Using Exit Interview Methodology to Understand Experiences and Meaningful Change in Angelman Syndrome
The TANGELO trial examined the tolerability and safety of the locked-nucleic acid-modified antisense oligonucleotide rugonersen (RO7248824) in patients aged 1 to 12 years with Angelman syndrome. The methodology of exit interviews conducted with patients’ caregivers to evaluate what constitutes a meaningful change in the condition is described.
Neuroscience Angelman Syndrome ASF-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 13 / Roche and Genentech
A Prospective, Longitudinal, Observational Clinical Trial in Individuals with Angelman syndrome to Enable Endpoint Development for Interventional Trials (FREESIAS)
Angelman syndrome (AS) is a neurodevelopmental disorder, for which there are currently no established endpoints to holistically measure meaningful change in clinical trials. The FREESIAS study aimed to identify potential endpoints by following individuals with AS and a number of typically developing children for one year. A wide range of clinical outcome assessments, digital health technologies and overnight electroencephalography were tested across key AS characteristics, performed at home and in clinic.
Neuroscience Angelman Syndrome CNS-2022

Sign up or login to unlock the full suite of MEDICALLY features
Aug 1 / Roche and Genentech
A Prospective, Longitudinal, Observational Study in Individuals With Angelman Syndrome to Enable Endpoint Development for Interventional Clinical Trials (FREESIAS)
Angelman syndrome (AS) is a neurodevelopmental disorder, for which there are currently no established endpoints to holistically measure meaningful change in clinical trials. The FREESIAS study aimed to identify potential endpoints by following individuals with AS and a number of typically developing children for one year. A wide range of clinical outcome assessments, digital health technologies and overnight electroencephalography were tested across key AS characteristics, performed at home and in clinic.
Neuroscience Angelman Syndrome ASF-2022

Sign up or login to unlock the full suite of MEDICALLY features
May 3 / Roche and Genentech
Developing Angelman Syndrome-Specific Clinician-Reported and Caregiver-Reported Measures to Support Holistic, Patient-Centered Drug Development
Valid and reliable measures reporting key symptoms and functional impairments of Angelman syndrome (AS) are required to support the development of patient-centered therapies. Here, we describe the development of disease-specific measures for use in clinical trials which incorporate the most important symptoms and functional impairments for the treatment of AS.
Neuroscience Angelman Syndrome INSAR-2021

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.